These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38861009)

  • 21. Activation of mGlu
    Frouni I; Hamadjida A; Kwan C; Bédard D; Nafade V; Gaudette F; Nuara SG; Gourdon JC; Beaudry F; Huot P
    Neuropharmacology; 2019 Nov; 158():107725. PubMed ID: 31351976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-parkinsonian effect of the mGlu
    Frouni I; Kwan C; Belliveau S; Hamadjida A; Bédard D; Nuara SG; Gourdon JC; Huot P
    Eur J Pharmacol; 2023 Jan; 939():175429. PubMed ID: 36502960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The highly selective mGlu
    Hamadjida A; Sid-Otmane L; Kwan C; Frouni I; Nafade V; Bédard D; Gagnon D; Wallman MJ; Rouillard C; Parent A; Parent M; Huot P
    Eur J Neurosci; 2020 Jun; 51(12):2412-2422. PubMed ID: 31944461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 5-HT
    Kwan C; Frouni I; Bédard D; Hamadjida A; Nuara SG; Gourdon JC; Huot P
    Eur J Neurosci; 2024 Mar; 59(6):1169-1176. PubMed ID: 37515363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective blockade of the 5-HT
    Kwan C; Nuara SG; Bédard D; Gaudette F; Gourdon JC; Beaudry F; Huot P
    Neuropharmacology; 2021 Jan; 182():108386. PubMed ID: 33152452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
    Hamadjida A; Nuara SG; Frouni I; Kwan C; Bédard D; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2139-2144. PubMed ID: 32601846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia.
    Finlay CJ; Jackson MJ; Fisher R; Bundgaard C; Rose S; Duty S
    J Parkinsons Dis; 2024; 14(2):245-259. PubMed ID: 38427500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
    Charvin D; Di Paolo T; Bezard E; Gregoire L; Takano A; Duvey G; Pioli E; Halldin C; Medori R; Conquet F
    Mov Disord; 2018 Oct; 33(10):1619-1631. PubMed ID: 30216534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.
    Beaudry F; Huot P
    J Neural Transm (Vienna); 2020 Oct; 127(10):1343-1358. PubMed ID: 32860561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.
    Kwan C; Nuara SG; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1685-1692. PubMed ID: 33963876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
    Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
    Mann E; Jackson M; Lincoln L; Fisher R; Rose S; Duty S
    J Parkinsons Dis; 2020; 10(3):959-967. PubMed ID: 32250315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
    Iderberg H; Maslava N; Thompson AD; Bubser M; Niswender CM; Hopkins CR; Lindsley CW; Conn PJ; Jones CK; Cenci MA
    Neuropharmacology; 2015 Aug; 95():121-9. PubMed ID: 25749357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia.
    Hurley MJ; Patel PH; Jackson MJ; Smith LA; Rose S; Jenner P
    Eur J Neurosci; 2007 Jul; 26(1):171-7. PubMed ID: 17614947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.
    Johnston TH; Huot P; Damude S; Fox SH; Jones SW; Rusche JR; Brotchie JM
    Parkinsonism Relat Disord; 2013 Feb; 19(2):260-4. PubMed ID: 22901956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Jenner P
    Mov Disord; 2001 Jul; 16(4):631-41. PubMed ID: 11481686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.
    Huot P; Johnston TH; Lewis KD; Koprich JB; Reyes MG; Fox SH; Piggott MJ; Brotchie JM
    J Neurosci; 2011 May; 31(19):7190-8. PubMed ID: 21562283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.